Heart valve study: which blood thinner prevents clots best after TAVR?

NCT ID NCT05493657

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study compares aspirin and clopidogrel to prevent leaflet thrombosis (blood clots on the valve) in 254 people who had a transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. After 4 weeks of both drugs, participants take either aspirin or clopidogrel alone for 6 months. The main goal is to see which drug reduces valve clots better, checked by CT scan at 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin and clopidogrel
What this could lead to: If successful, this could identify the better single antiplatelet drug to prevent dangerous blood clots on the new heart valve after TAVR, improving long-term safety.
What could go wrong: This is a relatively small, early-phase trial (254 people) comparing two common drugs, so the difference may be small or not apply to all patients. The study only follows patients for 6 months, so longer-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE AORTIC STENOSIS

Contacts and locations

Locations

Yonsei University Health System, Severance Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.